Loading
HKSEHealthcareBiotechnology
Latest quote
HK$53.90
+HK$0.90 · +1.70%
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
Latest quote
HK$53.90
+HK$0.90 · +1.70%
Regular session · HKT · Market data may be delayed.
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
Day range
Current HK$53.90
52-week range
Current HK$53.90
Regular session · HKT · Market data may be delayed.
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
Day range
Current HK$53.90
52-week range
Current HK$53.90
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI EAFE ETFIEFA6.28M0.00%196.63B USD0.07%$98.645-0.78%
Vanguard Total International Stock ETFVXUS6.12M0.00%646.2B USD0.05%$86.42-1.13%
Vanguard FTSE Developed Markets ETFVEA4.1M0.00%315B USD0.03%$72.0562-1.05%
iShares MSCI EAFE Small-Cap ETFSCZ3M0.02%13.23B USD0.40%$85.35-0.84%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.85M0.01%13.6B USD0.06%$157.6-1.20%
iShares Core MSCI Total International Stock ETFIXUS1.3M0.00%61.15B USD0.07%$96.405-1.19%
Schwab International Small-Cap Equity ETFSCHC1.02M0.02%5.77B USD0.06%$50.54-1.21%
ROBO Global Healthcare Technology and Innovation ETFHTEC898.13K1.20%74.99M USD0.80%$40.78-0.92%iShares Core MSCI EAFE ETFIEFAVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares MSCI EAFE Small-Cap ETFSCZVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares Core MSCI Total International Stock ETFIXUSSchwab International Small-Cap Equity ETFSCHCROBO Global Healthcare Technology and Innovation ETFHTECAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
